I loss it all. Sorry I have not been posting much the last two weeks. Creditors had me busy fighting just to keep the apartment and car. But no fear, I am back.
Vertex also has a second drug in development, VX-661. We don't have the critical phase 2 data yet, but CEO Jeff Leiden said in Monday's presentation that the company plans to push a combination of VX-661 and Kalydeco into phase 3 development. It appears Vertex is convinced the combination works even if the phase 2 data isn't polished enough for public consumption.
To get at the rest of the patients in the orange section, Vertex might have to add more drugs to the cocktail; it has a next-generation corrector ready to enter the clinic this year.
Even if Vertex can capture the whole pie, there's potential for increasing revenue by adding additional drugs to the combinations to increase efficacy.
Kalydeco helps to keep the gate open, allowing salts to pass through, reducing mucus buildup, and increasing patients' ability to breathe.
Vertex believes it can achieve Kalydeco sales of between $560 million and $580 million this year.
Vertex Pharmaceuticals Going to Get Fat on Cystic Fibrosis Pie
January 16, 2015
Cystic fibrosis affects 75,000 people in North America, Europe, and Australia, but it isn't a one-drug-fits-all kind of disease. Different mutations in the cystic fibrosis transmembrane conductance regulator, or CFTR gene, result in different problems with the protein, causing a build-up of mucus in patients' airways, intestines, and ducts of the pancreas.
Vertex Pharmaceuticals (NASDAQ: VRTX ) might only have a slice of the cystic fibrosis drug business at the moment, but it's looking to eat most of the pie.
The company used this slide in their JP Morgan Healthcare Conference presentation on Monday to illustrate the point:
RBC felt they were conned by this management and dropped them.I have never seen a bank who was hired as a promoter dump a upstart so fast.Downgraded Insmed out the door.
Management is;; and has been;; in the process of liquidating Insmed for the last 19 months.
If you have been an owner since this con started you have been liquidated by 2/3rds.The last third may take another 19 months but it will happen
VRTXVertex Pharmaceuticals Inc. said it would seek regulatory approval later this year for an
experimental cystic-fibrosis drug that helped produce a statistically significant improvement in patients' lung function compared with placebo in two late-stage studies.
If approved, the new pill... 22 k patients !